Saccharomyces cerevisiae expressing Gp43 protects mice against Paracoccidioides brasiliensis infection

PLoS One. 2015 Mar 19;10(3):e0120201. doi: 10.1371/journal.pone.0120201. eCollection 2015.

Abstract

The dimorphic fungus Paracoccidioides brasiliensis is the etiological agent of paracoccidioidomycosis (PCM). It is believed that approximately 10 million people are infected with the fungus and approximately 2% will eventually develop the disease. Unlike viral and bacterial diseases, fungal diseases are the ones against which there is no commercially available vaccine. Saccharomyces cerevisiae may be a suitable vehicle for immunization against fungal infections, as they require the stimulation of different arms of the immune response. Here we evaluated the efficacy of immunizing mice against PCM by using S. cerevisiae yeast expressing gp43. When challenged by inoculation of P. brasiliensis yeasts, immunized animals showed a protective profile in three different assays. Their lung parenchyma was significantly preserved, exhibiting fewer granulomas with fewer fungal cells than found in non-immunized mice. Fungal burden was reduced in the lung and spleen of immunized mice, and both organs contained higher levels of IL-12 and IFN-γ compared to those of non-vaccinated mice, a finding that suggests the occurrence of Th1 immunity. Taken together, our results indicate that the recombinant yeast vaccine represents a new strategy to confer protection against PCM.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antigens, Fungal / genetics
  • Antigens, Fungal / immunology
  • Antigens, Fungal / metabolism*
  • Fungal Proteins / genetics
  • Fungal Proteins / immunology
  • Fungal Proteins / metabolism*
  • Fungal Vaccines / immunology
  • Glycoproteins / genetics
  • Glycoproteins / immunology
  • Glycoproteins / metabolism*
  • Interferon-gamma / metabolism
  • Interleukin-2 / metabolism
  • Lung / drug effects
  • Lung / microbiology
  • Lung / pathology
  • Male
  • Mice
  • Paracoccidioides / genetics
  • Paracoccidioides / immunology*
  • Paracoccidioidomycosis / immunology
  • Paracoccidioidomycosis / pathology
  • Paracoccidioidomycosis / prevention & control*
  • Paracoccidioidomycosis / veterinary*
  • Saccharomyces cerevisiae / genetics
  • Saccharomyces cerevisiae / physiology*
  • Spleen / drug effects
  • Spleen / microbiology
  • Spleen / pathology
  • Vaccination

Substances

  • 43 kDa protein, Paracoccidioides
  • Antigens, Fungal
  • Fungal Proteins
  • Fungal Vaccines
  • Glycoproteins
  • Interleukin-2
  • Interferon-gamma

Grants and funding

This work was partially funded by Fundação de Amparo à Pesquisa do Estado de São Paulo—FAPESP (grant numbers 2006/60642-2; 2013/04088-0; 2014/05359-0 to M.C.R.-B. and 08/558316 to P.S.R.C.) (www.fapesp.br), and Conselho Nacional de Desenvolvimento Científico e Tecnológico, CNPq (grant number 306298/2013-9 to M.C.R.-B. and a scholarship to P.S.R.C.). M.A.A.-M. received a scholarship from Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, CAPES. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.